Fennec Pharmaceuticals Files 8-K
Ticker: FENC · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, financial-reporting
TL;DR
FENNEC PHARMACEUTICALS INC. filed an 8-K on 12/9/25. Check for updates.
AI Summary
Fennec Pharmaceuticals Inc. filed an 8-K on December 9, 2025, reporting on other events and financial statements. The company, previously known as Adherex Technologies Inc., is incorporated in British Columbia, Canada, and operates in the biological products sector.
Why It Matters
This filing provides an update on Fennec Pharmaceuticals' corporate events and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — Registrant
- Adherex Technologies Inc (company) — Former company name
- December 9, 2025 (date) — Date of earliest event reported
FAQ
What is the primary business of Fennec Pharmaceuticals Inc.?
Fennec Pharmaceuticals Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 9, 2025.
What were the previous names of Fennec Pharmaceuticals Inc.?
Fennec Pharmaceuticals Inc. was formerly known as Fennec Pharmaceuticals, Inc. (name change on 20140903) and prior to that, Adherex Technologies Inc (name change on 20021223).
Where is Fennec Pharmaceuticals Inc. incorporated?
Fennec Pharmaceuticals Inc. is incorporated in British Columbia, Canada.
What is the Commission File Number for Fennec Pharmaceuticals Inc.?
The Commission File Number for Fennec Pharmaceuticals Inc. is 001-32295.
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-12-09 16:02:02
Filing Documents
- fencf-20251209x8k.htm (8-K) — 52KB
- fencf-20251209xex99d1.htm (EX-99.1) — 42KB
- fencf-20251209xex99d1001.jpg (GRAPHIC) — 2KB
- 0001104659-25-119654.txt ( ) — 218KB
- fencf-20251209.xsd (EX-101.SCH) — 3KB
- fencf-20251209_lab.xml (EX-101.LAB) — 16KB
- fencf-20251209_pre.xml (EX-101.PRE) — 10KB
- fencf-20251209x8k_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On December 9, 2025, Fennec Pharmaceuticals Inc. (the "Company") announced the planned initiation of an investigator-sponsored clinical study ("IST") to be conducted by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK (sodium thiosulfate injection) for the prevention of cisplatin-induced ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors. The Phase I study (ClinicalTrials.gov Identifier: NCT07218913) is titled "Testing the Addition of PEDMARK to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors." The study is being conducted at City of Hope in Duarte, California, with Alexander Chehrazi-Raffle, M.D., serving as principal investigator. The study will evaluate whether the addition of PEDMARK to standard cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with metastatic testicular germ cell tumors. PEDMARK is currently approved in the United States for pediatric patients one month of age and older with localized, non-metastatic solid tumors and has received a Category 2A recommendation from the National Comprehensive Cancer Network for use in adolescent and young adult patients. The Company also disclosed that multiple additional investigator-initiated studies have been submitted and are currently under internal review, with others in advanced contracting or evaluation stages. A copy of the Company's press release announcing the investigator-sponsored study is attached hereto as Exhibit 99.1 and is incorporated herein by reference. .
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated December 9, 2025 Exhibit 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date December 9, 2025 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer